Homozygous FCGR3A‐158V alleles predispose to late onset neutropenia after CHOP‐R for diffuse large B‐cell lymphoma

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Abstract
Background

Recent reports suggest genetic polymorphisms influence susceptibility to rituximab‐induced late‐onset neutropenia (LON), which in turn may be a predictor of good outcome in B‐cell lymphoma.
Aims

We report the largest study to date assessing FCGR3AV158F polymorphisms in diffuse large B‐cell lymphoma (DLBCL) treated with cyclophosphamide/hydroxydaunorubicin/Oncovin (vincristine)/prednisone/rituximab (CHOPR). The influence of C1qAA276G polymorphisms in DLBCL, and the impact of both polymorphisms on susceptibility to LON and outcome were also examined.
Methods

115 DLBCL patients treated with CHOP‐R were compared with 105 healthy White people controls with regards to FCGR3AV158F and C1qAA276G polymorphisms. LON incidence and event‐free and overall survival (EFS and OS) were analysed for linkage to either polymorphism.
Results

The FCGR3AV158F but not the C1qAA276G polymorphism influenced the risk of developing LON. 50% of FCGR3A‐158V/V patients experienced LON. In contrast, only 7% V/F and 2% F/F experienced LON. The FCGR3A‐158V/V genotype was associated with LON compared with V/F (P = 0.028) and F/F genotypes (P = 0.005). Although no patients with either LON or FCGR3A‐158V homozygosity relapsed compared with 33% FCGR3A‐158F/F and 21% non‐LON, this did not translate into improved EFS or OS.
Conclusions

Polymorphic analysis may be a predictive tool to identify those at high risk of LON. Prospective studies are required to establish definitively if LON or FCGR3A‐158V/V genotype influences outcome.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2011.02587.x

Publication date: October 1, 2012

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more